Topics

FDA Approves Bavencio Plus Inlyta Combination for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

10:31 EDT 15 May 2019 | Speciality Pharma Journal

Darmstadt, Germany and New York, US, May 14, 2019 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with INLYTA® (axitinib) for the first-line treatment …

Original Article: FDA Approves Bavencio Plus Inlyta Combination for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Bavencio Plus Inlyta Combination for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...